REMission INDuction in very early Rheumatoid Arthritis - REMINDRA

niversity Medical Center Utrecht (UMCU)0 个研究点目标入组 267 人开始时间: 2016年9月28日最近更新: 2019年6月30日

试验速览

暂无简介。

•To be eligible to participate in this study, a subject must meet all of the following criteria:
•-Able and willing to give written informed consent
•-At least 18 years of age
•-Fulfilling 2010 ACR/EULAR criteria for RA (Appendix A.)
•-Patient reported symptom duration (joint stiffness, tenderness, pain, and/or swelling) < 12 months
•-Naïve for DMARD and biological treatment
•-Naïve for previous use of glucocorticoids for RA
•-DAS28 =>3.2
•-Have sufficient knowledge of the Dutch language to be able to comply with the requirements of the study protocol
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 267
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 267

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•-Being pregnant or a nursing women or a women of child bearing potential without (adequate) use of contraception
•-Having any other inflammatory rheumatic disease than RA, except for secondary Sjögren’s syndrome
•-Having contraindications for the use of MTX/HCQ/methylprednisolone/GOL.

发起方

niversity Medical Center Utrecht (UMCU)